openPR Logo
Press release


10-30-2017 11:09 AM CET | Health & Medicine

Press release from: Pharamceutical

Point-of-care infectious disease diagnostics market has grown manifold over the last 20 years, driving major profits across value chains. The industry witnessed slow growth during 2005–2010 before taking a major leap with adoption of mobile technology. Point-of-care testing or bed-side testing refers to tests that are performed near the site of patient care. These tests can potentially improve detection and management of infectious diseases by reducing time between tests and results. These testing aids in reduction of operating times, postoperative care time, and high-dependency, thereby ensuring optimal use of professional time. Urine test strips and imaging tests such as portable ultrasound and ECG tests are some examples of point-of-care testing. Point-of-care testing for infectious diseases includes rapid, reliable, and affordable tests for HIV infection, malaria, dengue fever, hepatitis, influenza, and pneumonia. Point-of-testing for infectious diseases exhibit a major opportunity for pharmacy services for expansion. Improvement in disease outcomes, simple and accurate tests, and rapid disease outcome and results are few of the advantages of point-of-care testing.

The billion dollar point-of-care infectious disease diagnostic market is expected to grow at a substantial rate over the forecast period (2016–2024).

Advancements in molecular diagnostics coupled with miniaturization of devices to drive the point-of-care infectious disease diagnostics market

Advancements in technological molecular diagnostics has boosted adoption of point-of-care solutions. The industry is also expected to grow with changing lifestyle. Currently, over 60% of population uses mobile phone. As a result, whole healthcare system has changed wherein portable devices has taken a key place.

Furthermore, growing preference for personalized medicine would create lucrative opportunity for point-of-care testing market in the near future.

Request For Sample Copy@

Point-of-Care Infectious Disease Diagnostics Market Taxonomy:

Coherent Market Insights has segmented the point-of-care infectious disease diagnostics products market by

Therapeutic application
End Users
On the basis of type of diseases, the Global POC Infectious Disease Diagnostics market can be segmented as follows:

On the basis of end user, the Global POC Infectious Disease Diagnostics market can be segmented as follows:

North America is the leading market for point-of-care infectious disease diagnostics products

On the basis of geography, the point-of-care infectious disease diagnostics market can be segmented into four major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America holds a leading position in the market, followed by Europe. The prime factors responsible for growth of POC infectious disease diagnostics market in these regions are rapidly increasing prevalence of infectious diseases and growing demand for rapid and accurate test results. According to the National Ambulatory Medical Care Survey, the number of visits to physician offices for infectious and parasitic diseases was recorded to be around 23.6 million in 2010. However, the market in Asia Pacific is expected to grow at the highest CAGR during the forecast period, due to presence of a large population base. The factors which would accentuate growth of point-of-care infectious disease diagnostics industry in Asia Pacific are increased government funding towards development of point-of-care diagnostic kits and rapidly changing healthcare infrastructure in emerging countries such as China, India, Vietnam, Malaysia, and Indonesia. Also, reduction in number of hospital bed required, reduction in number of outpatient clinic visits, and lesser patient waiting times are few of the potential factors that would propel growth in adoption of point-of-care infectious disease diagnostics in Asia Pacific during the forecast period.

Abbott Laboratories, Roche Diagnostics Ltd are driving market expansion through high R&D spending along with direct distribution channel in emerging economies

The point-of-care infectious disease diagnostics market is driven by technological advancements and hence, various companies are continuously making efforts to develop novel products pertaining to infectious disease diagnostics. Some of the top companies operating in the POC infectious disease diagnostics market are Abbott Laboratories, Roche Diagnostics Ltd., Beckman Coulter, Inc., Bayer AG, Becton Dickinson and Company, Johnson and Johnson, Alere Inc., Nipro Diagnostics Inc., Nova Biomedical, Siemens AG, Trinity Biotech PLC, Danaher Corporation, and Spectral Diagnostics.

Get More Details On this Report:

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Visit our news Website:

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Shah here

News-ID: 792723 • Views: 208

More Releases from Pharamceutical

Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast

All 5 Releases